• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CCL21 和 CCL19 的偏向信号传递不依赖于 N 端差异,而是明显依赖于 CCR7 的趋化因子核心结构域和细胞外环 2。

Biased Signaling of CCL21 and CCL19 Does Not Rely on N-Terminal Differences, but Markedly on the Chemokine Core Domains and Extracellular Loop 2 of CCR7.

机构信息

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Biotechnology Institute Thurgau (BITg), University of Konstanz, Kreuzlingen, Switzerland.

出版信息

Front Immunol. 2019 Sep 13;10:2156. doi: 10.3389/fimmu.2019.02156. eCollection 2019.

DOI:10.3389/fimmu.2019.02156
PMID:31572374
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6753178/
Abstract

Chemokine receptors play important roles in the immune system and are linked to several human diseases. Targeting chemokine receptors have so far shown very little success owing to, to some extent, the promiscuity of the immune system and the high degree of biased signaling within it. CCR7 and its two endogenous ligands display biased signaling and here we investigate the differences between the two ligands, CCL21 and CCL19, with respect to their biased activation of CCR7. We use (BRET) based signaling assays and Transwell migration assays to determine how swapping of domains between the two ligands affect their signaling patterns and how receptor mutagenesis impacts signaling. Using chimeric ligands we find that the chemokine core domains are central for determining signaling outcome as the lack of β-arrestin-2 recruitment displayed by CCL21 is linked to its core domain and not N-terminus. Through a mutagenesis screen, we identify the extracellular domains of CCR7 to be important for both ligands and show that the two chemokines interact differentially with extracellular loop 2 (ECL-2). By using modeling, we propose a link between ECL-2 interaction and CCR7 signal transduction. Our mutagenesis study also suggests a lysine in the top of TM3, K130, to be important for G protein signaling, but not β-arrestin-2 recruitment. Taken together, the bias in CCR7 between CCL19 and CCL21 relies on the chemokine core domains, where interactions with ECL-2 seem particularly important. Moreover, TM3 selectively regulates G protein signaling as found for other chemokine receptors.

摘要

趋化因子受体在免疫系统中发挥着重要作用,与多种人类疾病有关。由于免疫系统的复杂性和高度偏向性信号传递,迄今为止,针对趋化因子受体的靶向治疗效果甚微。CCR7 及其两种内源性配体显示出偏向性信号传递,在此我们研究了两种配体 CCL21 和 CCL19 在激活 CCR7 方面的差异。我们使用基于 BRET 的信号检测和 Transwell 迁移实验来确定配体之间的结构域交换如何影响它们的信号模式,以及受体突变如何影响信号传递。使用嵌合配体,我们发现趋化因子核心结构域对于确定信号传递结果至关重要,因为 CCL21 缺乏β-arrestin-2 募集与其核心结构域而非 N 端有关。通过突变筛选,我们确定 CCR7 的细胞外结构域对于两种配体都很重要,并表明这两种趋化因子与细胞外环 2(ECL-2)相互作用不同。通过建模,我们提出了 ECL-2 相互作用与 CCR7 信号转导之间的联系。我们的突变研究还表明,TM3 顶部的一个赖氨酸 K130 对于 G 蛋白信号传递很重要,但对于β-arrestin-2 募集则不重要。总之,CCR7 在 CCL19 和 CCL21 之间的偏向性依赖于趋化因子核心结构域,其中与 ECL-2 的相互作用似乎尤为重要。此外,正如其他趋化因子受体所发现的那样,TM3 选择性地调节 G 蛋白信号传递。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/773fbbdd462c/fimmu-10-02156-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/d83505dc3063/fimmu-10-02156-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/655cb888be9f/fimmu-10-02156-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/a952729dbbab/fimmu-10-02156-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/2845e9c33448/fimmu-10-02156-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/430b9ee2c846/fimmu-10-02156-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/773fbbdd462c/fimmu-10-02156-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/d83505dc3063/fimmu-10-02156-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/655cb888be9f/fimmu-10-02156-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/a952729dbbab/fimmu-10-02156-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/2845e9c33448/fimmu-10-02156-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/430b9ee2c846/fimmu-10-02156-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/755d/6753178/773fbbdd462c/fimmu-10-02156-g0006.jpg

相似文献

1
Biased Signaling of CCL21 and CCL19 Does Not Rely on N-Terminal Differences, but Markedly on the Chemokine Core Domains and Extracellular Loop 2 of CCR7.CCL21 和 CCL19 的偏向信号传递不依赖于 N 端差异,而是明显依赖于 CCR7 的趋化因子核心结构域和细胞外环 2。
Front Immunol. 2019 Sep 13;10:2156. doi: 10.3389/fimmu.2019.02156. eCollection 2019.
2
Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes.趋化因子受体CCR7在白细胞中由其配体CCL19和CCL21引发的常见且有偏向性的信号通路。
J Leukoc Biol. 2016 Jun;99(6):869-82. doi: 10.1189/jlb.2MR0815-380R. Epub 2016 Jan 4.
3
CCL19 with CCL21-tail displays enhanced glycosaminoglycan binding with retained chemotactic potency in dendritic cells.CCL19 与 CCL21 尾缀融合后增强了糖胺聚糖结合能力,同时保持了对树突状细胞的趋化活性。
J Leukoc Biol. 2018 Aug;104(2):401-411. doi: 10.1002/JLB.2VMA0118-008R. Epub 2018 May 16.
4
Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21.在CCL19而非CCL21连接后,抑制蛋白3介导CCR7的内吞作用。
J Immunol. 2008 Oct 1;181(7):4723-32. doi: 10.4049/jimmunol.181.7.4723.
5
Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7.CC趋化因子受体7的两种内源性配体介导的差异脱敏、受体磷酸化、β抑制蛋白募集及ERK1/2激活
J Biol Chem. 2004 May 28;279(22):23214-22. doi: 10.1074/jbc.M402125200. Epub 2004 Mar 30.
6
Selective Boosting of CCR7-Acting Chemokines; Short Peptides Boost Chemokines with Short Basic Tails, Longer Peptides Boost Chemokines with Long Basic Tails.选择性增强 CCR7 作用趋化因子;短肽增强带有短碱性尾巴的趋化因子,长肽增强带有长碱性尾巴的趋化因子。
Int J Mol Sci. 2022 Jan 26;23(3):1397. doi: 10.3390/ijms23031397.
7
Increased levels of CCR7 ligands in carotid atherosclerosis: different effects in macrophages and smooth muscle cells.颈动脉粥样硬化中 CCR7 配体水平升高:在巨噬细胞和平滑肌细胞中的不同作用。
Cardiovasc Res. 2014 Apr 1;102(1):148-56. doi: 10.1093/cvr/cvu036. Epub 2014 Feb 11.
8
CCR7 signaling inhibits T cell proliferation.CCR7信号传导抑制T细胞增殖。
J Immunol. 2007 Nov 15;179(10):6485-93. doi: 10.4049/jimmunol.179.10.6485.
9
The C-terminal peptide of CCL21 drastically augments CCL21 activity through the dendritic cell lymph node homing receptor CCR7 by interaction with the receptor N-terminus.CCL21 的 C 末端肽通过与受体 N 端相互作用,极大地增强了 CCL21 活性,通过树突状细胞淋巴节点归巢受体 CCR7。
Cell Mol Life Sci. 2021 Nov;78(21-22):6963-6978. doi: 10.1007/s00018-021-03930-7. Epub 2021 Sep 29.
10
Biased signaling of G protein-coupled receptors - From a chemokine receptor CCR7 perspective.G蛋白偶联受体的偏向性信号传导——以趋化因子受体CCR7为例
Gen Comp Endocrinol. 2018 Mar 1;258:4-14. doi: 10.1016/j.ygcen.2017.07.004. Epub 2017 Jul 8.

引用本文的文献

1
Co-stimulation with equibiaxial strain and pre-osteoblast co-culture differentiates monocytes in a bone model.在骨模型中,等双轴应变与前成骨细胞共培养共同刺激可使单核细胞分化。
MRS Commun. 2025;15(3):462-469. doi: 10.1557/s43579-025-00711-2. Epub 2025 Apr 17.
2
Systematic Assessment of Human CCR7 Signalling Using NanoBRET Biosensors Points towards the Importance of the Cellular Context.系统评估人类 CCR7 信号转导利用 NanoBRET 生物传感器指向细胞环境的重要性。
Biosensors (Basel). 2024 Mar 14;14(3):142. doi: 10.3390/bios14030142.
3
Chemokine CCL19 promotes type 2 T-cell differentiation and allergic airway inflammation.

本文引用的文献

1
The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects.μ-阿片受体偏向性激动剂的利用:奥列吗啡,一种具有降低不良反应的阿片类镇痛药。
Curr Pain Headache Rep. 2019 Mar 18;23(5):31. doi: 10.1007/s11916-019-0773-1.
2
Ligand binding to human prostaglandin E receptor EP at the lipid-bilayer interface.配体在双层脂界面与人前列腺素 E 受体 EP 的结合。
Nat Chem Biol. 2019 Jan;15(1):18-26. doi: 10.1038/s41589-018-0131-3. Epub 2018 Dec 3.
3
Crystal structure of the endogenous agonist-bound prostanoid receptor EP3.
趋化因子 CCL19 促进 2 型 T 细胞分化和过敏性气道炎症。
J Allergy Clin Immunol. 2024 Feb;153(2):487-502.e9. doi: 10.1016/j.jaci.2023.10.024. Epub 2023 Nov 11.
4
NMR indicates the N-termini of PSGL1 and CCR7 bind competitively to the chemokine CCL21.核磁共振表明,P选择素糖蛋白配体1(PSGL1)和趋化因子受体7(CCR7)的N端与趋化因子CCL21竞争性结合。
Biochem Biophys Rep. 2023 Jul 29;35:101524. doi: 10.1016/j.bbrep.2023.101524. eCollection 2023 Sep.
5
Heparin Specifically Interacts with Basic BBXB Motifs of the Chemokine CCL21 to Define CCR7 Signaling.肝素特异性结合趋化因子 CCL21 的碱性 BBXB 基序来定义 CCR7 信号。
Int J Mol Sci. 2023 Jan 14;24(2):1670. doi: 10.3390/ijms24021670.
6
In silico analysis and in planta production of recombinant ccl21/IL1β protein and characterization of its in vitro anti-tumor and immunogenic activity.重组 ccl21/IL1β 蛋白的计算机分析和植物体内生产及其体外抗肿瘤和免疫原性活性的表征。
PLoS One. 2022 Aug 29;17(8):e0261101. doi: 10.1371/journal.pone.0261101. eCollection 2022.
7
Cellular Electrical Impedance as a Method to Decipher CCR7 Signalling and Biased Agonism.细胞电阻抗作为破译 CCR7 信号和偏性激动剂的方法。
Int J Mol Sci. 2022 Aug 10;23(16):8903. doi: 10.3390/ijms23168903.
8
New Insights of CCR7 Signaling in Dendritic Cell Migration and Inflammatory Diseases.CCR7信号在树突状细胞迁移和炎症性疾病中的新见解
Front Pharmacol. 2022 Feb 25;13:841687. doi: 10.3389/fphar.2022.841687. eCollection 2022.
9
Selective Boosting of CCR7-Acting Chemokines; Short Peptides Boost Chemokines with Short Basic Tails, Longer Peptides Boost Chemokines with Long Basic Tails.选择性增强 CCR7 作用趋化因子;短肽增强带有短碱性尾巴的趋化因子,长肽增强带有长碱性尾巴的趋化因子。
Int J Mol Sci. 2022 Jan 26;23(3):1397. doi: 10.3390/ijms23031397.
10
Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?癌症免疫治疗领域中的趋化因子:它们及其受体如何用于将冷肿瘤转变为热肿瘤?
Cancers (Basel). 2021 Dec 16;13(24):6317. doi: 10.3390/cancers13246317.
内源性激动剂结合的前列腺素受体 EP3 的晶体结构。
Nat Chem Biol. 2019 Jan;15(1):8-10. doi: 10.1038/s41589-018-0171-8. Epub 2018 Dec 3.
4
Structural basis for ligand recognition of the human thromboxane A receptor.人血栓烷 A 受体配体识别的结构基础。
Nat Chem Biol. 2019 Jan;15(1):27-33. doi: 10.1038/s41589-018-0170-9. Epub 2018 Dec 3.
5
Viral GPCR US28 can signal in response to chemokine agonists of nearly unlimited structural degeneracy.病毒 GPCR US28 可以响应结构几乎无限简并的趋化因子激动剂发出信号。
Elife. 2018 Jun 8;7:e35850. doi: 10.7554/eLife.35850.
6
CCL19 with CCL21-tail displays enhanced glycosaminoglycan binding with retained chemotactic potency in dendritic cells.CCL19 与 CCL21 尾缀融合后增强了糖胺聚糖结合能力,同时保持了对树突状细胞的趋化活性。
J Leukoc Biol. 2018 Aug;104(2):401-411. doi: 10.1002/JLB.2VMA0118-008R. Epub 2018 May 16.
7
A unique signal sequence of the chemokine receptor CCR7 promotes package into COPII vesicles for efficient receptor trafficking.趋化因子受体 CCR7 的独特信号序列可促进其包装到 COPII 小泡中,从而实现有效的受体运输。
J Leukoc Biol. 2018 Aug;104(2):375-389. doi: 10.1002/JLB.2VMA1217-492R. Epub 2018 Mar 30.
8
Molecular Mechanisms of GPCR Signaling: A Structural Perspective.G 蛋白偶联受体信号转导的分子机制:结构视角。
Int J Mol Sci. 2017 Nov 24;18(12):2519. doi: 10.3390/ijms18122519.
9
Trends in GPCR drug discovery: new agents, targets and indications.G蛋白偶联受体(GPCR)药物研发趋势:新药物、靶点与适应症
Nat Rev Drug Discov. 2017 Dec;16(12):829-842. doi: 10.1038/nrd.2017.178. Epub 2017 Oct 27.
10
Biased signaling of G protein-coupled receptors - From a chemokine receptor CCR7 perspective.G蛋白偶联受体的偏向性信号传导——以趋化因子受体CCR7为例
Gen Comp Endocrinol. 2018 Mar 1;258:4-14. doi: 10.1016/j.ygcen.2017.07.004. Epub 2017 Jul 8.